Wu Yangfeng, Yu Xin, Zhu Yidan, Shi Chuan, Li Xian, Jiang Ronghuan, Niu Sheng, Gao Pei, Li Shenshen, Yan Lijing, Maulik Pallab K, Guo Guifang, Patel Anushka, Gao Runlin, Blumenthal James A
The George Institute for Global Health at Peking University Health Science Centre (PUHSC), Beijing, China.
Clinical Research Institute, Institute of Advanced Clinical Medicine, Peking University, Beijing, China.
Lancet Reg Health West Pac. 2024 Jul 1;48:101126. doi: 10.1016/j.lanwpc.2024.101126. eCollection 2024 Jul.
Acute coronary syndrome (ACS) often co-occurs with depression, which adversely affects prognosis and increases medical costs, but effective treatment models are lacking, particularly in low-resource settings. This study aims to determine the effectiveness of an ACS and depression integrative care (IC) model compared to usual care (UC) in improving depression symptoms and other health outcomes among patients discharged for ACS in Chinese rural hospitals.
A multicentre, randomised controlled trial was conducted in sixteen rural county hospitals in China, from October 2014 to March 2017, to recruit consecutively all ACS patients aged 21 years and older after the disease stablised and before discharge. Patients were randomly assigned in a 1:1 ratio to receive either the IC or UC, stratified by hospital and depression severity. Patients allocated to IC received an ACS secondary prevention program and depression care including case screening, group counselling, and individual problem-solving therapy. Patients allocated to UC received usual care. The primary outcome was change in Patient Health Questionnaire-9 (PHQ-9) from baseline to 6 and 12 months. Main secondary outcomes included major adverse events (MAEs) composed of all-cause death, non-fatal myocardial infarction and stroke, and all-cause re-hospitalisation. Participants were followed up till March 2018. All data were collected in person by trained assessors blinded to treatment group and MAEs were adjudicated centrally. This trial is registered with ClinicalTrials.gov, NCT02195193.
Among 4041 eligible patients (IC: 2051; UC: 1990), the mean age was 61 ± 10 years and 63% were men. The mean PHQ-9 score lowered at both 6 and 12 months in both groups but was not lower in IC compared to UC at 6 months (mean difference (MD): -0.04, 95% confidence interval (CI): -0.20, 0.11) or 12 months (MD: -0.06, 95% CI: -0.21, 0.09). There were no treatment group differences for MAEs or other secondary outcomes except for secondary prevention medications at 12 months (45.2% in IC vs 40.8% in UC; relative risk: 1.21, 95% CI: 1.05-1.40). Pre-specified subgroup analyses showed that IC, compared to UC, may be more effective in lowering PHQ-9 scores in women, older patients, and patients with low social support, but less effective in moderately and severely depressed patients (all p for interaction <0.05).
The study found that the cardiology nurse-led ACS- and depression-integrated care, compared to usual care, did not improve depression symptoms in all patients discharged with ACS. Greater benefits in certain subgroups warrants further studies.
R01MH100332 National Institute of Mental Health.
急性冠状动脉综合征(ACS)常与抑郁症同时发生,这对预后产生不利影响并增加医疗成本,但缺乏有效的治疗模式,尤其是在资源匮乏的地区。本研究旨在确定与常规治疗(UC)相比,ACS与抑郁症综合护理(IC)模式在改善中国农村医院因ACS出院患者的抑郁症状和其他健康结局方面的有效性。
2014年10月至2017年3月,在中国16家农村县级医院进行了一项多中心随机对照试验,连续招募所有年龄在21岁及以上、病情稳定且出院前的ACS患者。患者按1:1比例随机分配接受IC或UC,按医院和抑郁严重程度分层。分配到IC组的患者接受ACS二级预防计划和抑郁护理,包括病例筛查、团体咨询和个体问题解决疗法。分配到UC组的患者接受常规护理。主要结局是患者健康问卷-9(PHQ-9)从基线到6个月和12个月的变化。主要次要结局包括由全因死亡、非致命性心肌梗死和中风组成的主要不良事件(MAE)以及全因再次住院。参与者随访至2018年3月。所有数据由对治疗组不知情的经过培训的评估人员亲自收集,MAE由中心判定。本试验已在ClinicalTrials.gov注册,注册号为NCT02195193。
在4041名符合条件的患者中(IC组:2051名;UC组:1990名),平均年龄为61±10岁,63%为男性。两组在6个月和12个月时PHQ-9平均得分均降低,但在6个月时IC组与UC组相比未降低(平均差值(MD):-0.04,95%置信区间(CI):-0.20,0.11),在12个月时也未降低(MD:-0.06,95%CI:-0.21,0.09)。除12个月时的二级预防药物外,MAE或其他次要结局在治疗组之间无差异(IC组为45.2%,UC组为40.8%;相对风险:1.21,95%CI:1.05-1.40)。预先设定的亚组分析表明,与UC组相比,IC组在降低女性、老年患者和社会支持低的患者的PHQ-9得分方面可能更有效,但在中度和重度抑郁患者中效果较差(所有交互作用p<0.05)。
研究发现,与常规护理相比,由心脏病学护士主导的ACS与抑郁症综合护理并不能改善所有因ACS出院患者的抑郁症状。某些亚组中的更大益处值得进一步研究。
美国国立精神卫生研究所R01MH100332基金。